Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Fate Therapeutics

Fate Therapeutics

A company developing therapies for the treatment of cancer and immune disorders

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of next-generation cellular immunotherapies for cancer and immune disorders. Fate's cells of interest are the cells of the immune system. The company is headquartered in San Diego, California and was founded in 2007 by Rudolf Jaenisch.

They are also pioneering a novel approach to cell therapy by using renewable master induced pluripotent stem cell (iPSC) lines generated from the company's proprietary iPSC product platform to derive cell therapy products that can be delivered off-the-shelf for the treatment of a large number of patients.

Fate's cell therapy product pipeline comprises of immuno-oncology programs, including off-the-shelf NK- and T-cell products derived from the master iPSC lines, and immuno-regulatory programs, including products to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease.

The company's immuno-oncology pipeline is comprised of FATE-NK100, a donor derived natural killer (NK) cell cancer immunotherapy that is being evaluated in three Phase 1 clinical trials. Each of these trials focus on one of the following types of cancer, AML, ovarian, and solid tumors. Other products in the preclinical stage include iPSC-derived NK cell and T-cell immunotherapies, FT500, FT516, FT538, and FT819,

Fate's immuno-regulation pipeline on the other hand is comprised of ProTmune and ToleraCyte. ProTmune is a programmed cellular immunotherapy developed for patients with hematologic malignancies and rare genetic disorders that seek curative outcomes through hematopoietic cell transplantation (HCT). This next-generation donor cell graft that is being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease. ToleraCyte is a pharmacologically programmed CD30+ cell therapy with potent immuno-regulatory properties being developed for the treatment of autoimmune and inflammatory diseases.


Fate Therapeutics was founded by Alexander Rives.
May 5, 2011
Fate Therapeutics raises a $35,988,360 series B round from ARCH Venture Partners, Astellas Venture Management, OVP Venture Partners, Polaris Partners and Venrock.
November 29, 2007
Fate Therapeutics raises a $12,000,000 series A round from ARCH Venture Partners, OVP Venture Partners, Polaris Partners and Venrock.

Funding Rounds


Further Resources


Off-the-shelf cell therapy for cancer? Fate Therapeutics to make its case at ASH

Arlene Weintraub



Ben Adams
August 20, 2021
Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop.
Alex Keown
June 7, 2021
Shares of Fate climbed nearly 4% in premarket trading after it announced positive interim data from a Phase I study of FT516 for patients with relapsed / refractory B-cell lymphoma.
Ben Adams
March 25, 2021
Fate Therapeutics' long-standing Chief Scientific Officer Daniel Shoemaker, Ph.D., will be leaving the cell therapy biotech this summer.


Golden logo
By using this site, you agree to our Terms & Conditions.